Orphan Drugs: New thinking on RWE generation and value
From clinical trial planning and better education of HCPs to meeting the demands of diverse stakeholder groups, real-world evidence (RWE) is increasingly playing a pivotal role in the successful development and launch of an orphan drug. But how can pharma generate persuasive RWE that supports their proposition and meets stakeholders needs? Why are patient-reported outcomes growing in importance? How can AI deliver better insights from wearable technology? In this report experts in the field examine the RWE challenges and identify practical solutions.
Companies
Novartis, Lilly, Pfizer, Merck, BioMarin Pharmaceutical, Bluebird Bio, Insilico Medicine, Terumo Blood and Cell Technologies, PTC Therapeutics, Centogene, Celgene, Vertex
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook